Clinical Trial Update: A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579) [Phase 1]

View source ↗

Summary

Phase 1 study of oral posaconazole in immunocompromised children was terminated; results posted in 2016 regarding safety, tolerance, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fungal Infections

Drugs mentioned

• POSACONAZOLE (POSACONAZOLE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Fungal Infections | Phase 1 | Status: TERMINATED | Results posted: 2016-04-15